UBS initiated coverage of Amrize (AMRZ) with a Neutral rating and $53 price target The company offers attractive growth potential over the medium-term but short-term headwinds persist, the analyst tells investors in a research note. The firm says key investor debate is what multiple Amrize should fundamentally trade on. It sees limited upside from current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.